Acotec Scientific Holdings (HKSE:06669) LT-Debt-to-Total-Asset : 0.12 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Acotec Scientific Holdings's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.12.

Acotec Scientific Holdings's long-term debt to total assets ratio increased from Dec. 2022 (0.03) to Dec. 2023 (0.12). It may suggest that Acotec Scientific Holdings is progressively becoming more dependent on debt to grow their business.

Acotec Scientific Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Acotec Scientific Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings LT-Debt-to-Total-Asset Chart

Acotec Scientific Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

0.14

0.06

0.01

0.03

0.12

Acotec Scientific Holdings Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial					0.02	0.03	0.13	0.12	-

Acotec Scientific Holdings LT-Debt-to-Total-Asset Calculation

Acotec Scientific Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	216.633	/	1762.14
	=	0.12

Acotec Scientific Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	216.633	/	1762.14
	=	0.12

Acotec Scientific Holdings (HKSE:06669) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Acotec Scientific Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Acotec Scientific Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

7W3:Germany

Address

16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN

Website

http://www.acotec.cn

Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.

Executives

Vistra Trust (singapore) Pte. Limited	2301 Trustee
Nexus Partners Group Limited	2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited	2101 Beneficial owner
Li Jing	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p.	2201 Interest of corporation controlled by you
Cpe Funds Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited	2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited	2101 Beneficial owner
Cpe Holdings Limited	2201 Interest of corporation controlled by you
Cpe Holdings International Limited	2201 Interest of corporation controlled by you
Cpe Gof Gp Limited	2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p.	2201 Interest of corporation controlled by you
Boston Scientific Corporation	2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings Headlines

No Headlines